Patents by Inventor Ticong Huang

Ticong Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine
    Patent number: 11773079
    Abstract: The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: October 3, 2023
    Assignees: Chia Tai Tianqing Pharmaceutical Group Co, Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.
    Inventors: Ticong Huang, Huifeng Xiao, Rui Zhao, Fei Liu, Wei Wei, Hongjiang Xu, Xiaojin Wang, Jingli Wu
  • Crystalline of compound as c-Met kinase inhibitor and preparation method therefor and use thereof
    Patent number: 11279676
    Abstract: The present application falls within the field of medicinal chemistry, relates to the crystalline of a compound as a c-Met kinase inhibitor, and specifically relates to the crystalline of N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and a preparation method therefor, a crystalline composition thereof, and a pharmaceutical composition thereof, as well as the use of the crystalline for treating diseases associated with the inhibition of growth factor receptor protein tyrosine kinase activity. The crystalline of the present application has excellent properties in at least one of the following aspects: pharmacokinetics, bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, etc.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: March 22, 2022
    Inventors: Feng Gong, Ticong Huang, Haishan Zang, Shibo Zhang, Rui Zhao, Fei Liu
  • 1,3,5-TRIAZINE DERIVATIVE SALT, CRYSTAL, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
    Publication number: 20210246119
    Abstract: The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.
    Type: Application
    Filed: April 27, 2021
    Publication date: August 12, 2021
    Inventors: Ticong Huang, Huifeng Xiao, Rui Zhao, Fei Liu, Wei Wei, Hongjiang Xu, Xiaojin Wang, Jingli Wu
  • Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine methanesulfonic acid salt
    Patent number: 11021464
    Abstract: The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: June 1, 2021
    Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd, Centaurus Biopharma Co., Ltd
    Inventors: Ticong Huang, Huifeng Xiao, Rui Zhao, Fei Liu, Wei Wei, Hongjiang Xu, Xiaojin Wang, Jingli Wu
  • CRYSTALLINE OF COMPOUND AS C-MET KINASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20210047272
    Abstract: The present application falls within the field of medicinal chemistry, relates to the crystalline of a compound as a c-Met kinase inhibitor, and specifically relates to the crystalline of N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and a preparation method therefor, a crystalline composition thereof, and a pharmaceutical composition thereof, as well as the use of the crystalline for treating diseases associated with the inhibition of growth factor receptor protein tyrosine kinase activity. The crystalline of the present application has excellent properties in at least one of the following aspects: pharmacokinetics, bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, etc.
    Type: Application
    Filed: March 1, 2019
    Publication date: February 18, 2021
    Applicants: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Advenchen Laboratories Nanjing Ltd.
    Inventors: Feng GONG, Ticong HUANG, Haishan ZANG, Shibo ZHANG, Rui ZHAO, Fei LIU
  • 1,3,5-TRIAZINE DERIVATIVE SALT, CRYSTAL, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
    Publication number: 20190352281
    Abstract: The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.
    Type: Application
    Filed: January 22, 2018
    Publication date: November 21, 2019
    Inventors: Ticong Huang, Huifeng Xiao, Rui Zhao, Fei Liu, Wei Wei, Hongjiang Xu, Xiaojin Wang, Jingli Wu
  • KINASE ACTIVITY REGULATING COMPOUND INTERMEDIATES PREPARATION METHOD
    Publication number: 20180346418
    Abstract: The present application relates to a preparation method of intermediate compounds with formula II and formula III of a compound (N-{3-[3-(9H-purin-6-yl) pyridin-2-ylamino]-4-chloro-2-fluorophenyl}-3-fluoropropane-1-sulfonamide) for regulating kinase activity.
    Type: Application
    Filed: November 25, 2016
    Publication date: December 6, 2018
    Inventors: Jijun LI, Yan Zhu, Huting Wang, Yongxin Han, Ticong Huang, Xinlu Li, Rui Zhao, Xiquan Zhang